Epacs (exchange proteins directly activated by cAMP) are guanine-nucleotide-exchange factors for the Raslike small GTPases Rap1 and Rap2. Epacs were discovered in 1998 as new sensors for the second messenger cAMP acting in parallel to PKA (protein kinase A). As cAMP regulates many important physiological functions in brain and heart, the existence of Epacs raises many questions regarding their role in these tissues. The present review focuses on the biological roles and signalling pathways of Epacs in neurons and cardiac myocytes. We discuss the potential involvement of Epacs in the manifestation of cardiac and central diseases such as cardiac hypertrophy and memory disorders.
Introduction
cAMP is a universal second messenger which is produced from ATP by adenylate cyclase upon activation of G s PCRs (G s -protein-coupled receptors) [1] . Pivotal in shaping and controlling intracellular cAMP gradients are PDEs (phosphodiesterases) [2] . cAMP is one of the most important second messengers because it is involved in a wide range of cell-type-specific effects, such as cell growth and cell differentiation. In brain and heart, cAMP regulates many physiological processes such as memory and contraction respectively. Besides these physiological roles, various actions of cAMP can be altered in cardiovascular and brain disorders such as heart failure and AD (Alzheimer's disease).
PKA (protein kinase A) and cyclic-nucleotide-gated channels were thought to be the only two direct effectors of cAMP, until the identification of Epac (exchange protein directly activated by cAMP) 1 and Epac2 in 1998 [3, 4] . Epacs are GEFs (guanine-nucleotide-exchange factors) for the Ras-like GTPases Rap1 and Rap2. They activate the small G-protein Rap by exchanging bound GDP for GTP, with GTPaseactivating proteins returning them to their inactive GDPbound states [5] . Recent data from the use of Epac agonists such as 8-pCPT-2 -O-Me-cAMP [8-(4-chloro-phenylthio)-2 -O-methyladenosine-3 ,5 -cAMP] have revealed that these cAMP-sensitive GEFs play critical roles in various physiological and pathophysiological processes; these include memory formation, inflammation and cardiac remodelling, thus identifying Epac as physiologically important and as a possible pharmacological target for the treatment of human disorders [5] [6] [7] .
In the present review, we begin with an introduction to the Epac structure and mechanisms of action. We next describe the role of these cAMP sensors in brain and heart, and discuss the potential implication of Epac in CNS (central nervous system) and cardiac disorders.
Epacs
Two isoforms of Epac exist, Epac1 and Epac2, which are coded by two distinct genes, RAPGEF3 and RAPGEF4 respectively [3, 4] . Epac isoforms respond to physiologically relevant cAMP concentrations and can be activated by GsPCRs that are positively linked to adenylate cyclase [7] . Although expressed in almost all tissues, Epacs have different patterns of expression and are developmentally regulated [8] . Epac1 is widely expressed, but particularly abundant in kidney and heart, whereas Epac2 is predominant in the brain and adrenal gland [4] . Epacs are characterized by an Nterminal regulatory region and a C-terminal catalytic region ( Figure 1) . A shorter N-terminal splice variant of Epac2 named Epac2B has been recently identified in the adrenal gland, suggesting that alternative splicing events may add further to the complexity of the functional characterization of Epac isoforms [9] . The N-terminal regulatory region of Epac contains a DEP (dishevelled, Egl-10, pleckstrin) domain, which is responsible for membrane association, and a highaffinity CNB (cyclic-nucleotide-binding) domain (in vitro K d of 1-4 μM) [5, 10] (Figure 1 ). Epac1 and Epac2 share a Cterminal catalytic core with an identical domain organization that consists of a REM (Ras-exchange motif) domain, a RA (Ras-association) domain, and a Cdc25 (cell division cycle 25) homology GEF domain responsible for Epac GDP/GTP exchange activity on Rap GTPases [11] .
Epac1 and Epac2 are structurally close, but Epac2 possesses an additional CNB domain at the N-terminal end,
Figure 1 Schematic representation of Epac multidomain proteins
The regulatory region of Epac contains one or two CNB domains and a DEP domain. Epac2B is a splice variant of Epac2 and lacks CNB-A. CNB-B binds cAMP directly with high affinity. The catalytic region consists of a GEF domain, a REM and a RA domain. The GEF domain is responsible for the exchange of GDP with GTP on Rap GTPases.
named CNB-A. This CNB-A of Epac2 binds cAMP with a 20-fold lower affinity than the conserved CNB-B and does not affect activation of Epac2 by cAMP [12] . Crystallography studies have shown that, in the absence of cAMP, the Nterminal regulatory region of Epac acts as an autoinhibitory domain by sterically blocking the access of Rap proteins to the catalytic site. Binding of cAMP to Epac causes a conformational change in the protein, allowing Epac catalytic region to interact with and to activate its effector Rap [13] .
In the cell, Epac is found at many locations such as the plasma membrane, the nuclear membrane, perinuclear regions, the cytosol and mitochondria. In neonatal and adult rat ventricular myocytes, Epac1 shows sarcolemmal and perinuclear linear localization [14, 15] . The various subcellular localizations of Epac can be connected with its numerous downstream effectors [5, 11] . Indeed, besides Rap, Epac has been shown to activate a plethora of other effectors such as Ras and Rho GTPases, PLC (phospholipase C), MAPKs (mitogen-activated protein kinases), PKB (protein kinase B)/Akt and PI3Ks (phosphoinositide 3-kinases) [16] . Depending on their cellular localization and molecular partners, Epacs activate different downstream effectors [7] . Thus the coupling of Epac to a specific signalling pathway is determined by its localization to subcellular compartments, explaining the different biological effects of Epac inside a given cell. This indicates that Epac signalling is spatially and temporally regulated by diverse anchoring mechanisms. In this sense, Epac has been shown to exert its cellular function with anchoring proteins such as AKAPs (A-kinaseanchoring proteins) and PSD-95 (postsynaptic density 95) (see below) [14, 17, 18] . PDEs are critical regulators of cAMP compartmentation since they sculpt local cAMP gradients to regulate the activation of spatially localized signalling through sequestered PKA and Epac subpopulations [2] .
Physiological roles of Epac in brain
As discussed below, we are just at the beginning of discovering the Epac mechanism of action in the CNS, but a few studies point out the importance of Epac in the regulation of various neuronal functions (Figure 2 ).
Neuronal growth and differentiation
The normal development of organisms requires a tight co-ordination between growth and differentiation. The differentiation of neuronal cells is important for the regular function of the brain. Thus there is interest in understanding the molecular signalling mechanisms that regulate cell proliferation and differentiation. In a number of cells, most notably those of neuronal origin, cAMP is a key regulator of cell proliferation, differentiation and survival, and plays important roles in numerous biological processes such as learning and memory formation [19] . Together or not with PKA, Epac contributes to the regulation of neuronal differentiation, neurite outgrowth and axon regeneration, implying a role for this cAMP-GEF in the development and maintenance of the nervous system. Initial evidence that Epac activation influences neuronal differentiation came from the observations that an Epac-selective agonist, 8-pCPT-2 -O-Me-cAMP, induced neurite outgrowth in rat phaeochromocytoma PC12 cells and human SH-SY5Y cells [20, 21] . Additional studies in PC12 cells showed that the effect of Epac to convert cAMP from a proliferative into a differentiation-promoting signal occurred through its ability to extend the duration of PKA-dependent ERK (extracellular-signal-regulated kinase) 1/2 activation, leading to enhanced neurite outgrowth [22] . Interestingly, Epacinduced PC12 neuronal differentiation is regulated by the neuropeptide PACAP38 (pituitary adenylate cyclaseactivating polypeptide 38) receptor, a member of the G s PCR family [23] . The signalling pathway linking PACAP38 receptor/Epac to neurite outgrowth of PC12 cells involves Rit, a close relative of Ras, in a manner that does not appear to rely upon the Epac effector Rap or the direct regulation of Rit by Epac [23] . Epac may also co-operate with neurotrophins such as the brain-derived neurotrophic factor to regulate the phenotypic differentiation of noradrenergic neurons [24] . The observation that Epac regulates PKB/Akt signalling strengthens its role in neuronal differentiation [18] .
Of note, recent studies indicate that Epac and PKA play opposing roles in regulating attractive and repulsive axon guidance respectively [25] , a process which guides axons to their appropriate targets during nervous system development. Direct activation of Epac with 8-pCPT-2 -OMe-cAMP promotes neurite outgrowth of adult rat dorsal root ganglion sensory neurons. In addition, Epac, but not PKA, is required to mediate cAMP-dependent axon regeneration on cryosections of adult spinal cord in vitro [26] . Therefore Epac may provide a promising target for Physiological and pathological roles are presented in blue and red respectively. Pathological roles are in red or green, indicating respectively that Epac expression induces or prevents the pathological mechanism. If distinct signalling pathways are described for a same biological effect, they are separated by a semi-colon. BIM, Bcl-2-interacting member protein; CaN, calcineurin; PI3K, phosphoinositide 3-kinase); PLD, phospholipase D; STEF, Sif-and Tiam1-like exchange factor.
inducing axon regeneration after injury [26] . In pre-Bötzinger complex, which is an essential part of the respiratory network, Epac regulates neurite outgrowth and the bursting activity of pre-Bötzinger neurons, suggesting that this cAMP-GEF may be involved in reinforcement of breathing activity by cAMP [27] .
Memory and learning
cAMP is an important second messenger involved in both synaptic plasticity and memory [29] . Thus activation of Epac by cAMP in the brain is likely to exert significant functional consequences in these processes. Consistent with its prominent expression in the CNS, several behavioural studies have demonstrated that Epac modulates some aspects of memory performance such as memory retrieval. For instance, intracerebral injection of the Epac activator 8-pCPT-2 -OMe-cAMP was shown to enhance memory in a contextdependent fear-conditioning paradigm [30, 31] . Interestingly, both Epac and PKA are required to rescue retrieval in noradrenaline-deficient dopamine β-hydroxylase-knockout mice that are impaired in contextual fear memory [32] . In contrast, it was reported that Epac enhanced the formation of long-term memory in the hippocampus and appeared to do so independently of PKA, thus demonstrating the importance of Epac-mediated signalling in memory consolidation [33] . Further support for the role for Epac on cognition came from electrophysiological experiments in the CA1 region of the hippocampus, which is a model system for the study of longterm synaptic plasticity such as LTP (long-term potentiation) and LTD (long-term depression). Indeed, 8-pCPT-2 -OMe-cAMP enhanced maintenance of LTP, a phenomenon commonly believed to be important for the mechanisms of learning and memory [34] . The effect of Epac on synaptic plasticity was also demonstrated by the study of Ster et al. [35] who showed that Epac induced LTD in hippocampal CA1 excitatory synapses in a p38 MAPK -, Ca 2 + -and protein synthesis-dependent manner.
Neuronal excitability and remodelling
Epac activation has been reported to increase excitatory neurotransmission in the CNS and facilitate neurotransmitter release at the glutamatergic synapses of the rat brain calyx of Held [36] [37] [38] . At the crayfish neuromuscular junction, Epac along with HCN (hyperpolarization-activated cyclic nucleotide) cation channels modulate neurotransmission via activation of Rap1 [39] . In cultured cerebellar granule neurons, Epac activates the ERK/p38 MAPK pathway via Rap proteins and modulates postsynaptic excitability [40] . Further functional studies in sensory neurons showed that Epac was also involved in the activation of PKC (protein kinase C) in response to a β 2 -adrenergic receptor stimulation. This cross-talk between Epac and PKC sensitizes pain receptors and augments the sensitivity to mechanical pain [41, 42] . In addition, the role for Epac in increasing the pain response may be pronounced in inflammation, during which Epac1 expression is up-regulated in the dorsal root ganglions [43] . It is proposed that antagonizing Epac1 up-regulation in sensory neurons could be a new strategy for treatment of patients with chronic pain. Finally, in suprachiasmatic nuclei of the hypothalamus, it has been reported that Epac represents a novel core component of the circadian pacemaker [44] .
Compelling evidence is now accumulating about the formation of molecular complexes in distinct cellular compartments that influence Epac signalling and cellular function [7] . The study of Woolfrey et al. [45] in cortical neurons illustrates this point nicely. The authors showed that recruitment of Epac2 to synapses by the postsynaptic adhesion molecule NL3 (neuroligin 3), mediated by the scaffold protein PSD-95, resulted in an increase in Epac2 activation and Rap activity. As enhanced Epac2 activity promotes spine shrinkage and increases spine dynamics, it suggests that this molecular complex may offer a pathway that NL3 may act through to modulate dendritic spine remodelling in cortical pyramidal neurons [45, 46] . In the same study, it was reported the dopamine D 1 /D 5 receptor regulates synapse structural remodelling via Epac2 [45] . The multidomain structure of Epac indicates that it may have multiple binding partners. In this sense, Epac interacts with the nociceptor GRK2 (G-protein-coupled receptor kinase 2). It was shown that a decrease in the expression level of GRK2 enhances activation of the Epac/Rap1 signalling and leads to prolonged inflammatory hyperalgesia in sensory neurons [47] .
Epac in CNS disorders
Because Epac orchestrates signalling events that regulate important neuronal functions, it appears reasonable that defects in Epac genes such as mutations or pathophysiological changes in Epac signalling may underlie certain neurological disorders. Although evidence is still limited, several reports now support the involvement of Epac in the manifestation of CNS diseases ( Figure 2 ). As Epac2 influences dendritic spine remodelling under normal conditions, alterations in Epac signalling are likely to cause defective or excessive synapse destabilization, which may contribute to a variety of CNS disorders. In this sense, rare missense mutations in the gene encoding Epac2 found in individuals with autism affected synaptic protein distribution and spine morphology [45] . Nicotine self-administration increases Epac2 expression in rat prefrontal cortex and there is an association of SNPs (single nucleotide polymorphisms) in Epac2 with nicotine dependence [48] . SNPs in the gene encoding Epac1 have been associated with anxiety and depression [49] .
Expression levels of Epacs may vary under pathological conditions. For instance, Epac2, but not Epac1, was significantly increased in prefrontal cortex and hippocampus of post-mortem tissue samples from depressed suicide victims [50] . McPhee et al. [51] reported an up-regulation of the mRNA for Epac1 and a down-regulation of the mRNA for Epac2 in the brain region associated with AD. Direct evidence for a role for Epac in AD came from studies in primary neurons showing that this cAMP sensor regulates the processing of the APP (amyloid precursor protein), a key protein involved in AD [52] . Specifically, Epac activates via a cross-talk between Ras and Rho small G-protein subfamilies, the α-secretase pathway to cleave APP in its extracellular domain and release a large soluble N-terminal ectodomain named sAPPα (soluble APPα) into the extracellular space [53, 54] . The α cleavage is of physiological interest because secreted sAPPα has neuroprotective properties and potent memory-enhancing effects [52] .
Physiological roles of Epac in heart
The myocardium is composed primarily of a collection of specialized muscle cells called cardiac myocytes whose physiological roles such as contraction are highly regulated by cAMP. Co-ordinated contraction of cardiac myocytes requires proper electrical excitation mediated by GJ (gap junction) formation. GJs are formed by connexins and Cx43 (connexin43) is the most predominantly expressed connexin isoform in cardiomyocytes. In cultured rat neonatal cardiomyocytes, Epac/Rap1 signalling increases Cx43 recruitment at cell-cell contact and enhances adherens junctions formation which is a prerequisite for GJ assembly [55] . In the same cellular system, Epac/Rap/PLC signalling increases intercellular permeability via PKCε-dependent phosphorylation of Cx43 [56] .
Given the importance of cAMP and Ca 2 + in cardiac function, several studies aimed at determining the role for Epac in Ca 2 + handling [57] . Initial experiments performed in neonatal rat cardiomyocytes showed that the Epac-specific cAMP analogue 8-pCPT-2 -O-Me-cAMP produced bursts of Ca 2 + transients [58] . In electrically stimulated adult mouse cardiac myocytes, a PLCε-dependent increase in the [Ca 2 + ] i (intracellular Ca 2 + concentration) transient amplitude has been reported, suggesting a role for Epac in excitationcontraction coupling [59] . Following β-AR (β-adrenergic receptor) stimulation, a Epac/Rap/PLCε/PKCε/CaMKII (Ca 2 + /calmodulin-dependent protein kinase II) signalling pathway regulates SR (sarcoplasmic reticulum) Ca 2 + release in mouse cardiac myocytes [59, 60] . However, the situation is different in rat ventricular cardiac myocytes. Indeed, acute stimulation of Epac with 8-pCPT-2 -O-Me-cAMP induces a decrease in the [Ca 2 + ] i transient amplitude and this is correlated with an increase in cardiac myocyte contraction via PLC-, PKC-and CaMKII-dependent phosphorylation of sarcomeric proteins such as cardiac myosin-binding protein C and troponin I [61, 62] . In line with its role in cell contraction, Epac may be involved in the positive inotropic effect of the vasoactive peptide urocortin [63] .
Epac appears also to regulate other important biological processes in the heart. For instance, roflumilast, a PDE4 inhibitor has been shown to protect NO-induced cardiac myocyte apoptosis via both cAMP/PKA-and Epacdependent pathways [64] . In cardiac fibroblasts, overexpression of Epac1 inhibits TGFβ1 (transforming growth factor β1)-induced collagen synthesis, suggesting that a decrease in Epac expression is required for profibrotic response [65] . Consistent with these data, Epac is also involved in the inhibitory effect of A 2 R (adenosine-2 receptor) on angiotensin II-stimulated collagen synthesis in cardiac fibroblasts [66] . These observations suggest a role for Epac in the regulation of cardiac fibrosis.
Epac and cardiac hypertrophy
Cardiac myocyte hypertrophy is the compensatory response of the heart to stress and is characterized by non-mitotic growth, addition of new sarcomeres, fetal gene expression and specific changes in ion channel properties. Maladaptive cardiac hypertrophy can progress to heart failure, a leading cause of morbidity and mortality in industrialized countries [67] . Interestingly, Epac expression is increased in different animal models of myocardial hypertrophy and heart failure. In rat myocardium, Epac1 is up-regulated at the onset of cardiac pressure overload-induced hypertrophy [15] . mRNA for both Epac1 and Epac2 increased in mice hearts during chronic isoprenaline infusion which is another model of left ventricular hypertrophy [8] . Furthermore, we found that Epac1 protein was significantly up-regulated in left ventricular samples from patients with heart failure [15] .
Direct evidence of its role in the regulation of cardiac growth came from the observation that Epac1 activation led to morphological changes associated with an increase in cell surface area, protein synthesis and the expression of cardiac hypertrophic markers such as the atrial natriuretic factor [15, 58] . In isolated rat adult cardiac myocytes, Epac1 has been shown to be activated by the β-AR, a prototypical member of the G-protein-coupled receptor superfamily [15] . β-AR serves as the most powerful regulatory mechanism to enhance myocardial performance in response to stress or exercise [68] . Although acute stimulation of the β-AR pathway has beneficial effects on heart function, its chronic activation leads to hypertrophic growth and ventricular dysfunction and ultimately to the development of heart failure [68, 69] . We therefore investigated the role for Epac in β-AR-induced myocyte hypertrophy. We found that silencing Epac1 expression blocked the hypertrophic effect of a non-selective β-AR agonist, isoprenaline, in primary cardiac myocytes [15] .
The contribution of Epac to the hypertrophic effect of β-AR was PKA-independent. Epac hypertrophic signalling involves the small GTPases Rap2B, Rac and H-Ras, PLC, the phosphatase calcineurin and its downstream transcription factor NFAT (nuclear factor of activation T-cells) [15, 57, 58] (Figure 2) . Moreover, Epac activation induced HDAC (histone deacetylase) 4 and HDAC5 nuclear exports, with the consequent activation of the prohypertrophic transcription factor MEF2 (myocyte enhancer factor 2) in a CaMKIIdependent manner [57] [61, 70] . This increase in RyR activity might also trigger ventricular arrhythmia. In this sense, it has been reported that Epac activation results in ventricular arrhythmogenesis in the whole mouse heart. The arrythmogenesis and the altered Ca 2 + handling due to Epac activation were significantly decreased by CaMKII inhibition [71] . Altogether, these data suggest that Epac contributes to the progression of maladaptive cardiac hypertrophy in response to β-AR stimulation. This cAMP sensor may represent an attractive therapeutic target for the treatment of cardiac hypertrophy leading to heart failure and associated arrhythmia.
Conclusions
Although we are just beginning to functionally characterize Epacs, the evidence described in the present paper demonstrates that these cAMP sensors play important roles in various physiological processes such as cognition, memory and intercellular communication. The development and the use of specific Epac conditional and temporal transgenic mouse models and new Epac ligands, including inhibitors, will certainly help us to understand better the physiological roles of Epacs in the near future. Another major challenge will be to determine whether Epac1 and Epac2 have distinct cellular functions and to characterize their hormonal regulation in vivo. Recent research now supports the involvement of Epac in the manifestation of certain diseases, such as cardiac hypertrophy and cognitive disorders, suggesting that Epacs may represent attractive therapeutic targets for the treatment of various cardiac and central disorders. The manifestation of Epacs in certain diseases is supported further by the observation that Epacs may influence key cellular processes regulating cell death and survival such as apoptosis, autophagy and plasmalemmal sealing [72] [73] [74] Depending on the tissue and the cellular type, selective activation or inhibition of Epac may have beneficial effects in a given pathological condition. Therefore, with the aim of therapeutic intervention, a major challenge for the future will be to develop novel Epac-specific compounds in order to modulate Epac-regulated signalling events with reduced side effects. 
